Treatment With SU11248 in Patients With Neuroendocrine Tumors
To assess the safety and efficacy of SU11248 in patients with Neuroendocrine Tumors.
Neuroendocrine Tumors
DRUG: Sunitinib
Radiographic objective disease response, From screening until disease progression or discontinuation of study
To assess safety (adverse events and lab abnormalities), From screening until patient death or discontinuation of study|To assess patient-reported outcomes and treatment-related symptoms, From screening until patient death or discontinuation of study|To assess pharmacokinetics and biomarkers, From screening until patient death or discontinuation of study|To assess overall survival at 1 year, From screening until patient death or discontinuation of study|To assess other measures of antitumor efficacy including TTP and survival, From screening until patient death or discontinuation of study
To assess the safety and efficacy of SU11248 in patients with Neuroendocrine Tumors.